Keywords: Merck Serono, Merck KGaA, Symphogen, Sym004, Colorectal cancer, Worldwide rights

Merck Serono gains rights to Ph II cancer drug from Symphogen for up to 475 million euros

Article | 06 September 2012

Print This

Privately-held Danish drug developer Symphogen A/S announced this morning that it has signed an exclusive worldwide license agreement with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in